INAB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.7M
-4.3%
4.9M
-6.3%
5.3M
+4.6%
5.0M
+26.9%
4.0M
R&D
2.6M
+4.3%
2.5M
-4.6%
2.6M
-1.3%
2.6M
+25.9%
2.1M
SG&A
2.1M
-13.1%
2.4M
-8.0%
2.7M
+11.2%
2.4M
+28.0%
1.9M
Operating Income
-4721000
+4.3%
-4935000
+6.3%
-5266000
-4.6%
-5033000
-26.9%
-3967000
EBITDA
-4464000
+4.6%
-4680000
+6.8%
-5021000
-4.9%
-4788000
-28.6%
-3723000
Net Income
-4592000
+4.0%
-4781000
+6.1%
-5090000
-3.0%
-4942000
-28.2%
-3854000
EPS (Basic)
$-0.24
+4.0%
$-0.25
+3.8%
$-0.26
+67.1%
$-0.79
+7.1%
$-0.85
EPS (Diluted)
$-0.24
+4.0%
$-0.25
+3.8%
$-0.26
+67.1%
$-0.79
+7.1%
$-0.85
Shares (Diluted)
19.5M
+0.0%
19.5M
-0.0%
19.5M
+210.7%
6.3M
+38.1%
4.5M
IN8bio (INAB) — Financials